Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis.
Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis.
复制标题
尼妥珠单抗联合同期放化疗治疗局部晚期鼻咽癌的回顾性分析
DOI：
10.18632/oncotarget.8225
复制
发表时间：
2016-04-26
期刊：
影响因子：
--
通讯作者：
Wang H
中科院分区：
文献类型：
--
作者：
Liu ZG;Zhao Y;Tang J;Zhou YJ;Yang WJ;Qiu YF;Wang H
尼妥珠单抗是一种针对表皮生长因子受体（EGFR）的阻断性单克隆抗体。然而，关于尼妥珠单抗联合同步放化疗治疗局部晚期NPC患者的安全性和初步疗效知之甚少。在2011年至2013年期间，共招募了42名确诊患者。完全缓解38例（90.5%），部分缓解4例（9.5%）。在早期治疗反应评估时，没有患者发生疾病进展，ORR为100%。2年局部无复发生存率（LRFS）、无远处转移生存率（DMFS）和总生存率（OS）分别为96.4%、93.1%和96.6%。最常见的不良反应是粘膜炎（19例）和血液学毒性（14例），分别有6例和3例3/4级毒性。43例患者均未出现皮疹。因此，尼妥珠单抗联合同步放化疗治疗局部晚期鼻咽癌显示出令人鼓舞的结果，没有毒性蓄积，耐受性良好。
Nimotuzumab is a blocking monoclonal antibody against epidermal growth factor receptor (EGFR). However, little is known about the safety and preliminary efficacy of nimotuzumab combined with concurrent chemoradiotherapy in locally advanced NPC patients. A total of 42 patients diagnosed between 2011 and 2013 were enrolled. Our results demonstrated 38 patients had a complete response (90.5%), 4 patients had a partial response (9.5%). And no patients had progressive disease at early treatment response evaluation, giving an ORR of 100%. The 2-year local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS) and overall survival (OS) were 96.4%, 93.1% and 96.6% respectively. The most common adverse events were mucositis (19 patients), hematology toxicity (14 patients) with 6 and 3 cases of grade 3/4 toxicity respectively. Skin rash was not developed in our 43 patients. Thus, nimotuzumab combined with concurrent chemoradiotherapy showed encouraging outcomes in the treatment of locally advanced nasopharyngeal carcinoma, without accumulation of toxicity and well-tolerated.
登录
查看更多内容
Nimotuzumab 通过上调 IGFBP-3 促进 EGFR 过表达食管鳞状细胞癌细胞的放射敏感性。
影响因子：
7.4
作者：
Zhao L;He LR;Xi M;Cai MY;Shen JX;Li QQ;Liao YJ;Qian D;Feng ZZ;Zeng YX;Xie D;Liu MZ
通讯作者：
Liu MZ
影响因子：
11.5
作者：
Dorsey, Kelly;Agulnik, Mark
通讯作者：
Agulnik, Mark
DOI：
10.1186/1748-717x-8-20
发表时间：
2013-01-24
期刊：
Radiation oncology (London, England)
影响因子：
--
作者：
Saleh-Ebrahimi L;Zwicker F;Muenter MW;Bischof M;Lindel K;Debus J;Huber PE;Roeder F
通讯作者：
Roeder F
影响因子：
158.5
作者：
Bonner, JA;Harari, PM;Ang, KK
通讯作者：
Ang, KK
影响因子：
254.7
作者：
Torre, Lindsey A.;Bray, Freddie;Jemal, Ahmedin
通讯作者：
Jemal, Ahmedin